ArticleTurkish journal of medical sciences2025
Predictive impact of PI-RADS 3 lesion volume/total prostate volume ratio in prostate cancer diagnosis in biopsy-naïve patients.
Article in Turkish journal of medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/aim: To assess the potential of the ratio between PI-RADS 3 lesion volume and total prostate volume as a predictive parameter for guiding the decision to perform a biopsy in patients presenting with PI-RADS 3 lesions on multiparametric prostate magnetic resonance imaging (mpMRI). Materials and methods: A total of 749 patients who underwent mpMRI due to suspected prostate cancer between January 2014 and August 2023 were scanned. Based on predefined inclusion and exclusion criteria, 308 patients were included. Age, total prostate-specific antigen (PSA) value, prostate volume measured in mpMRI, mpMRI result, PI-RADS 3 lesion volume, and biopsy results were collected. The PI-RADS 3 ratio was calculated as PI-RADS 3 lesion volume/total prostate volume. PSA density (dPSA) was calculated. The patients were categorized according to their biopsy results as benign or malignant (subclassified by Gleason group grade), and the two groups were compared. Results: The average PI-RADS 3 ratio was 0.032 ± 0.002. There were 230 (74.7%) patients in the benign group and 78 (25.3%) patients in the malignant group. There was a statistically significant difference detected in average prostate volumes (p < 0.001), dPSA values (p = 0.001), and PI-RADS 3 ratios (p < 0.001). The receiver operating curve analysis of PI-RADS 3 ratio indicated an area under the curve of 0.643 ± 0.037. The optimal cut-off point was 0.026 with a sensitivity of 58.97% and a specificity of 66.96%. A positive, albeit weak, statistically significant relationship was found between PIRADS-3 ratios and dPSA values (rs ρ = 0.261 and p < 0.001). Conclusion: PI-RADS 3 ratio may serve as an auxiliary clinical parameter alongside age, dPSA, and lesion volume alone in identifying more refined candidates for biopsy in the goal of patient care individualization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.